Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms

BJU International

Volumn 109, Issue 12, 2012, Pages 1831-1840

  Kaplan, Steven A ^a   Roehrborn, Claus G ^b   Gong, Jason ^c   Sun, Franklin ^c   Guan, Zhonghong ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

blocker; antimuscarinic; fesoterodine; LUTS; men; overactive bladder; prostatic hyperplasia; signs and symptoms

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FESOTERODINE; PLACEBO; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; HEADACHE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERACTIVE BLADDER; OVERACTIVE BLADDER QUESTIONNAIRE; PARALLEL DESIGN; PATIENT PERCEPTION OF BLADDER CONDITION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URGENCY PERCEPTION SCALE; URINARY FREQUENCY; URINARY URGENCY; URINE FLOW RATE; URINE RETENTION; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 84861573150     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10624.x     Document Type: Article

References (31)

1. Irwin DE, Milsom I, Hunskaar S, et al,. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15
2. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S,. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 2009; 56: 14-20
3. Abrams P, Cardozo L, Fall M, et al,. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
4. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I,. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-95
5. Coyne KS, Wein AJ, Tubaro A, et al,. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 (Suppl.): 34-11
6. Abdel-Aziz KF, Lemack GE,. Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002; 3: 445-51
7. Patel AK, Chapple CR,. Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Nat Clin Pract Urol 2008; 5: 211-9
8. Gravas S, Melekos MD,. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment? Curr Opin Urol 2009; 19: 49-54
9. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB,. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20
10. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z,. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-28
11. Haylen BT, de Ridder D, Freeman RM, et al,. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20
12. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G,. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-6
13. Andersson KE, Chapple CR, Cardozo L, et al,. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94
14. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z,. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011; 65: 487-507
15. Herschorn S, Jones JS, Oelke M, Macdiarmid S, Wang JT, Guan Z,. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 Phase III studies. Urology 2010; 75: 1149-55
16. Coyne KS, Matza LS, Kopp Z, Abrams P,. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86
17. Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR,. Validation of the urinary sensation scale (USS). Neurourol Urodyn 2011; 30: 360-5
18. Barry MJ, Fowler FJ Jr, O'Leary MP, et al,. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57
19. Coyne K, Revicki D, Hunt T, et al,. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74
20. Cardozo L, Coyne KS, Versi E,. Validation of the Urgency Perception Scale. BJU Int 2005; 95: 591-6
21. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z,. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers. Eur Urol 2009; 56: 534-43
22. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W,. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-30
23. MacDiarmid SA, Peters KM, Chen A, et al,. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83: 1002-10
24. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z,. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061-7
25. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z,. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55: 472-9
26. Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z,. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration. BJU Int 2010; 106: 1332-8
27. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J,. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9
28. Roehrborn CG, McConnell JD, Lieber M, et al,. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
29. Martín-Merino E, García-Rodríguez LA, Masso-Gonzalez EJ, Roehrborn CG,. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182: 1442-8
30. Wyndaele JJ, Goldfischer ER, Morrow JD, et al,. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 560-7
31. Dmochowski RR, Peters KM, Morrow JD, et al,. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010; 75: 62-8